Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
18.98
-0.59 (-3.01%)
Dec 20, 2024, 4:00 PM EST - Market closed
Pacira BioSciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 694.96 | 674.98 | 666.82 | 541.53 | 429.65 | 421.03 | Upgrade
|
| Revenue Growth (YoY) | 4.40% | 1.22% | 23.14% | 26.04% | 2.05% | 24.83% | Upgrade
|
| Cost of Revenue | 255.38 | 260.93 | 284.09 | 195.8 | 176.75 | 178.83 | Upgrade
|
| Gross Profit | 439.58 | 414.05 | 382.73 | 345.73 | 252.9 | 242.2 | Upgrade
|
| Selling, General & Admin | 280.29 | 269.44 | 254.52 | 199.35 | 193.52 | 200.78 | Upgrade
|
| Other Operating Expenses | - | - | - | 42.91 | - | - | Upgrade
|
| Operating Expenses | 337.57 | 326.73 | 311.8 | 255.81 | 201.38 | 206.49 | Upgrade
|
| Operating Income | 102.01 | 87.32 | 70.93 | 89.92 | 51.52 | 35.71 | Upgrade
|
| Interest Expense | -15.28 | -20.31 | -39.98 | -31.75 | -25.67 | -23.63 | Upgrade
|
| Interest & Investment Income | 17.56 | 11.44 | 4.54 | 0.9 | 4.63 | 7.38 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.2 | -0.19 | -1.29 | -0.07 | 1.23 | 0.72 | Upgrade
|
| EBT Excluding Unusual Items | 104.48 | 78.28 | 34.21 | 59 | 31.71 | 20.18 | Upgrade
|
| Merger & Restructuring Charges | -8.79 | -3.07 | -11.25 | - | 0.04 | -5.06 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -10 | -2.6 | 1.62 | -5.7 | Upgrade
|
| Asset Writedown | - | - | -26.13 | - | - | - | Upgrade
|
| Legal Settlements | - | - | - | - | - | -3.5 | Upgrade
|
| Other Unusual Items | -150.61 | -13.5 | 26.48 | - | -13.28 | -16.67 | Upgrade
|
| Pretax Income | -54.91 | 61.7 | 13.3 | 56.4 | 20.09 | -10.75 | Upgrade
|
| Income Tax Expense | 35.82 | 19.75 | -2.61 | 14.42 | -125.43 | 0.27 | Upgrade
|
| Net Income | -90.73 | 41.96 | 15.91 | 41.98 | 145.52 | -11.02 | Upgrade
|
| Net Income to Common | -90.73 | 41.96 | 15.91 | 41.98 | 145.52 | -11.02 | Upgrade
|
| Net Income Growth | - | 163.72% | -62.10% | -71.15% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 46 | 46 | 46 | 44 | 43 | 42 | Upgrade
|
| Shares Outstanding (Diluted) | 46 | 52 | 47 | 46 | 44 | 42 | Upgrade
|
| Shares Change (YoY) | 0.49% | 11.69% | 1.99% | 4.46% | 5.22% | 1.47% | Upgrade
|
| EPS (Basic) | -1.96 | 0.91 | 0.35 | 0.95 | 3.41 | -0.27 | Upgrade
|
| EPS (Diluted) | -1.96 | 0.89 | 0.34 | 0.92 | 3.33 | -0.27 | Upgrade
|
| EPS Growth | - | 160.68% | -63.04% | -72.37% | - | - | Upgrade
|
| Free Cash Flow | 193.53 | 139.49 | 115.2 | 79.85 | 39.23 | 60.36 | Upgrade
|
| Free Cash Flow Per Share | 4.18 | 2.68 | 2.48 | 1.75 | 0.90 | 1.45 | Upgrade
|
| Gross Margin | 63.25% | 61.34% | 57.40% | 63.84% | 58.86% | 57.52% | Upgrade
|
| Operating Margin | 14.68% | 12.94% | 10.64% | 16.61% | 11.99% | 8.48% | Upgrade
|
| Profit Margin | -13.06% | 6.22% | 2.39% | 7.75% | 33.87% | -2.62% | Upgrade
|
| Free Cash Flow Margin | 27.85% | 20.67% | 17.28% | 14.75% | 9.13% | 14.34% | Upgrade
|
| EBITDA | 178.03 | 162.9 | 151.93 | 118.47 | 71.42 | 55.29 | Upgrade
|
| EBITDA Margin | 25.62% | 24.13% | 22.78% | 21.88% | 16.62% | 13.13% | Upgrade
|
| D&A For EBITDA | 76.03 | 75.57 | 81 | 28.55 | 19.91 | 19.58 | Upgrade
|
| EBIT | 102.01 | 87.32 | 70.93 | 89.92 | 51.52 | 35.71 | Upgrade
|
| EBIT Margin | 14.68% | 12.94% | 10.64% | 16.61% | 11.99% | 8.48% | Upgrade
|
| Effective Tax Rate | - | 32.00% | - | 25.57% | - | - | Upgrade
|
| Revenue as Reported | 694.96 | 674.98 | 666.82 | 541.53 | 429.65 | 421.03 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.